AELIX’s HTI HIV Vaccine Investigational Assets Acquired by Gilead Sciences

AELIX Therapeutics, a biopharmaceutical company backed by Ysios Capital based in Barcelona, Spain, that focuses on HIV vaccine development, today announced that Gilead Sciences, Inc. (Nasdaq: GILD), based in Foster City, Calif., USA, has acquired its HTI HIV investigational assets.

Thomas Hecht, Executive Chairman of AELIX, said: “We are excited that such a prominent company as Gilead, a leader in HIV treatment, prevention and cure research, has decided to acquire AELIX’s HTI therapeutic HIV vaccine investigational assets. The HTI vaccines have shown promising results in phase 1 and phase 2 clinical trials, and we are eager to see this immunogen move forward through this acquisition and potentially become an important aspect of the search for an HIV cure. We are thankful to our early-stage investors including Ysios Capital, which had the vision to support the development of potential HIV cure strategies.”

Christian Brander, CSO and co-founder of AELIX, who discovered the immunogen with his colleagues Drs. Beatriz Mothe and Anuska Llano at IrsiCaixa, added: “We are excited that our HTI T-cell immunogen is now in the hands of an innovative pharmaceutical company like Gilead Sciences, which has the tools and capabilities to further evaluate this asset as part of a potential approach to an HIV cure strategy.”

About Aelix Therapeutics

AELIX Therapeutics is a clinical stage biotechnology company based in Barcelona, Spain, focused on the development of a therapeutic HIV vaccine to be included in cure/eradication strategies. AELIX Therapeutics is a spin-off of HIVACAT, a Catalan public-private consortium conducting cutting-edge research in the field of AIDS, with the support of Fundació Glòria Soler. The company is backed by a syndicate of experienced Spanish and international investors including Ysios Capital, and 10K Lakes Fund II, L.P.